MOUNTAIN VIEW, Calif., April 10 /PRNewswire/ -- MAP Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on developing novel treatments for respiratory and CNS diseases, today announced that it will present a company update at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference in New York. The conference will be held April 11 - 12, 2007 at the Millennium Broadway. Timothy S. Nelson, MAP Pharmaceuticals’ President and CEO, will make the company’s presentation on Thursday, April 12, 2007, at 9:45 am (ET).
About MAP Pharmaceuticals
Located in Mountain View, California, MAP Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on developing novel treatments for respiratory and CNS diseases. The Company has completed Phase 2 clinical trials in two development programs: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraine. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com .
MAP Pharmaceuticals, Inc.
CONTACT: Lisa Johnson of MAP Pharmaceuticals, Inc., +1-650-386-3122, orljohnson@mappharma.com
Web site: http://www.mappharma.com//
